



A-BIO SECURES MAJOR DEAL WITH A GLOBAL PHARMACEUTICAL COMPANY

*Novo Nordisk and A-Bio Enter into a Master Service Agreement
for Process Development and Clinical Supply*

Singapore, 30th May 2005 – A-Bio Pharma Pte Ltd (A-Bio) today announced that it has entered into a multi-year Master Service Agreement with Novo Nordisk A/S (NYSE: NVO). Under the agreement, Novo Nordisk will engage A-Bio for process development and GMP clinical supply of biologics in its pipeline of biopharmaceutical projects.

“We are delighted by this exciting, multi-product collaboration with Novo Nordisk, a world leader in diabetes care,” said Dr George Wang, Managing Director of A-Bio. “Securing yet another international biopharmaceutical company as our long term partner is a substantial step towards strengthening our global customer base. This deal further reinforces A-Bio’s position in Asia as a leading biologics contract manufacturer.”

This exciting announcement comes after an earlier one in which A-Bio, a Bio*One Capital subsidiary, secured a process development and clinical supply service agreement with GlaxoSmithKline Biologicals (GSK Bio) late last year.

About A-Bio

A-Bio Pharma Pte Ltd is Asia’s leading biologics contract manufacturer which provides a full range of manufacturing solutions for mammalian cell culture systems: including process development, optimisation, manufacturing scale-up, GMP production, quality control and regulatory compliance. Based in Singapore, A-Bio started operations in November 2003 providing GMP manufacturing of clinical Phase I and Phase II biologics. Plans are underway to expand the capacity of this facility to meet increasing production needs globally. For more information on A-Bio, please contact the company at info@a-bio.com or visit www.a-bio.com.

Contact:

A-Bio Pharma Pte Ltd (company reg. no.: 200105467N)
Daniel Floerke
Senior Manager, Business Development
(65) 6796 9535